Every earnings call for ASTRAZEN — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ASTRAZEN · 5 transcripts · Healthcare · latest Q1 FY26AstraZeneca Pharma India Limited has 5 earnings calls on record here, a Healthcare company, most recently Q1 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue ₹1,716 cr (+32% YoY); EPS ₹46.3 (−27% YoY). Revenue from operations for FY24-25 reached ₹1,716 crore, representing a 32% YoY growth.
Read full transcript & analysisRevenue (FY24) ₹1,330 cr (+29% YoY); EPS ₹64.6 (+63% YoY). Total Revenue for FY23-24 reached ₹1,330 crores, representing a 29% YoY growth.
Read full transcript & analysisProduct Sales ₹947 cr (+24% YoY); Total Comprehensive Income ₹97 cr (+62% YoY); Profit Before Tax ₹134 cr. Product sales reached ₹947 crores (Rs. 9,470 million), representing a 24% YoY growth.
Read full transcript & analysisRevenue ₹761 cr (−2% YoY). Revenue from sales stood at ₹761.4 crores, a slight decline of 2% YoY due to generic competition in key brands.
Read full transcript & analysisRevenue ₹777 cr (−3% YoY); EBITDA Margin 17%; EPS ₹37.3. Registered annual sales of ₹776.8 crores (Rs. 7,768 million) for FY21, a decline of 3.1% YoY.
Read full transcript & analysis